Paper Details

  1. Home
  2. Paper Details

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.

Author: BadgettDarlene, BakshiRohit, BhasiKavitha, FeichterJoan, MinhasMiranda, MunschauerFrederick, PatrickKara, RamanathanMurali, Tamaño-BlancoMiriam, Weinstock-GuttmanBianca

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study characterized gene expression profiles in peripheral blood mononuclear cells of 22 relapsing multiple sclerosis (MS) patients receiving interferon-beta1a (IFN-beta) therapy. Gene expression was analyzed after the first dose and upon chronic dosing, as well as differences between good responders and partial responders. Results showed that approximately 35% of genes were up-regulated and 65% were down-regulated after IFN-beta treatment. Differences in gene expression profiles between good responders and partial responders were observed in pathways involved in immune response and cell signaling.
Paper Details　
Original Abstract of the Article :
PURPOSE: To characterize gene expression in multiple sclerosis (MS) patients after the first dose and chronic dosing of 30 microg, once weekly, intramuscular interferon-beta1a (IFN-beta) and to delineate the pharmacogenomic differences between Good Responders and Partial Responders to IFN-beta thera...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jneuroim.2008.09.004

データ提供：米国国立医学図書館（NLM）

Gene Expression in Multiple Sclerosis Patients

In the world of [multiple sclerosis (MS)], researchers are working diligently to understand the complex mechanisms of this disease. This study investigates the genomic effects of interferon-beta1a treatment in MS patients. It’s like exploring the intricate landscape of a desert, attempting to uncover the secrets hidden within its sands. The researchers analyzed gene expression profiles in peripheral blood mononuclear cells of MS patients before and after treatment with interferon-beta1a. Their findings suggest that interferon-beta1a treatment affects gene expression in a way that may be related to the patient's response to therapy.

Gene Expression Changes Reflect Treatment Response

The study found significant changes in gene expression following interferon-beta1a treatment in MS patients. Interestingly, the researchers observed differences in time profiles for gene expression changes between good responders and partial responders to the therapy. This suggests that gene expression analysis might be useful for predicting a patient's response to interferon-beta1a treatment. This is like discovering unique geological formations in the desert, each offering a different view of the landscape and hinting at the underlying processes at work.

Potential for Personalized Treatment Strategies

This study provides valuable insights into the potential of gene expression analysis for understanding and predicting individual responses to interferon-beta1a treatment in MS. This knowledge could lead to more personalized treatment strategies tailored to each patient's unique genetic profile, potentially improving treatment outcomes.

Dr.Camel's Conclusion

This study, like a detailed map of a vast desert, reveals the intricate changes in gene expression that occur in response to interferon-beta1a treatment. This research offers a unique perspective on MS and its treatment, highlighting the importance of understanding the individual genetic landscape of each patient. It’s like finding a hidden oasis in the desert of MS research, offering a glimpse of personalized treatment strategies in the future.

Date :
  1. Date Completed 2009-03-19
  2. Date Revised 2008-11-25
Further Info :

Pubmed ID

18950872

DOI: Digital Object Identifier

10.1016/j.jneuroim.2008.09.004

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.